Related Experiment Video
Updated: Jun 21, 2026
08:07
Rose Bengal Photothrombosis by Confocal Optical Imaging In Vivo: A Model of Single Vessel Stroke
Published on: June 23, 2015
Biodistribution processes as underestimated confounders in translational stroke research
1Department of Neurology, University Hospital Zurich, Frauenklinikstr. 26, CH-8091 Zurich, Switzerland. dirk.hermann@usz.ch
Current Medicinal Chemistry
|January 29, 2008
Summary
Limited progress in ischemic stroke pharmacological therapies highlights the need for better drug biodistribution studies. Precise brain accumulation research in animals and humans is crucial for improved dosing and trial success.
Area of Science:
- Neuroscience
- Pharmacology
- Translational Medicine
Background:
- Pharmacological therapies for ischemic stroke have shown limited success, with numerous neuroprotection trials failing in humans.
- The STAIR conferences critically reviewed past studies and offered recommendations, raising hopes for future neuroprotection strategies.
- The blood-brain barrier (BBB) significantly impacts brain pharmacotherapies by limiting drug entry and actively eliminating drugs via transporters.
Purpose of the Study:
- To address the challenges in developing effective pharmacological therapies for ischemic stroke.
- To highlight the critical role of the blood-brain barrier and drug biodistribution in therapeutic outcomes.
- To advocate for improved preclinical and clinical studies focusing on drug brain accumulation.
Main Methods:
- Review of previous neuroprotection trials and STAIR conference recommendations.
- Analysis of the blood-brain barrier's function as a barrier and its active transporter systems.
- Discussion of interspecies variability in drug transporters and its impact on predicting brain drug concentrations.
Main Results:
- Significant concerns exist regarding current research strategies for ischemic stroke neuroprotection.
- Drug transporters in the blood-brain barrier exhibit substantial interspecies variability, complicating prediction of drug concentrations across species.
- Drug biodistribution is a major confounding factor in the efficacy of pharmacological therapies.
Conclusions:
- More precise studies on drug brain accumulation are essential before initiating clinical trials in both animal models and humans.
- Improved understanding of drug biodistribution can lead to better dose selection for pharmacological interventions.
- Enhanced preclinical and clinical research on brain drug accumulation may increase the success rates of future ischemic stroke treatment trials.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:15Factors Affecting Drug Distribution: Organ Perfusion Rate
Drug distribution within the body is a complex process influenced by several factors, including perfusion rate, the rate at which the bloodstream transports drugs to tissue. This limitation becomes particularly significant when dealing with highly lipophilic drugs. In such cases, the rate at which the drug can move across membranes is crucial, and if the membrane is highly permeable to the drug, distribution becomes rate-limited by perfusion.
Perfusion rate-limited distribution relies on the...
Perfusion rate-limited distribution relies on the...
01:19Factors Affecting Drug Biotransformation: Biological
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
A recent model describes pravastatin's hepatobiliary excretion, mediated...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:27Confounding in Epidemiological Studies
Confounding in statistical epidemiology represents a pivotal challenge, referring to the distortion in the perceived relationship between an exposure and an outcome due to the presence of a third variable, known as a confounder. This variable is associated with both the exposure and the outcome but is not a direct link in their causal chain. Its presence can lead to erroneous interpretations of the exposure's effect, either exaggerating or underestimating the true association. This phenomenon...